Two-Year Results From Pfizer’s XELJANZ (Tofacitinib Citrate) ORAL Start Study Published in The New England Journal of Medicine

19-06-2014 Business Wire HealthComments (0)


Pfizer Inc. (NYSE:PFE) announced today the publication of two-year results from the ORAL Start study in the June 19 issue of The New England Journal of Medicine. ORAL Start is a 24-month Phase 3 study in patients with moderately to severely active rheumatoid arthritis who had not previously received methotrexate. The study showed that XELJANZ (tofacitinib citrate) 5 mg and 10 mg twice daily, as monotherapy (e.g., taken without methotrexate), inhibited the progression

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top